Navigation Links
Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
Date:4/14/2008

Direct Collection of Patient-Reported Outcomes (PROs) Improves Cancer Care

MEMPHIS, Tenn., April 14 /PRNewswire/ -- Supportive Oncology Services, Inc. (SOS), a noted leader in oncology research-based health information, announced today it has accrued over one million cancer patient self-reported assessments using the PACE(TM) electronic e/Tablet system. In October, 2000 medical oncologists at The West Clinic began collecting information directly from cancer patients via a wireless, touch screen e/Tablet system known as the Patient Assessment Care and Education (PACE) System. The clinicians were in search of better ways to monitor and manage symptoms in order to improve quality of life issues for cancer patients. Recently, the one millionth self-reported patient assessment was collected from a US-based practice via PACE (TM), establishing a milestone in the accrual of Patient Reported Outcomes (PROs) in the oncology community.

PACE(TM) provides a gender-specific, in-depth review of body systems and psychological/social well-being, facilitating a more focused and productive physician/patient encounter. "The PACE System prompts patients to tell me things they might otherwise forget," according to Pat Cobb, MD, Medical Oncologist with Hematology-Oncology Centers of the Northern Rockies in Billings, Montana. "Additionally, patients seem more comfortable sharing sensitive information such as symptoms of depression, suicide, and sexual dysfunction. I prefer to have the PACE assessment completed before meeting with the patient."

In recent reports, the value of PROs in caring for the patient and potentially predicting and avoiding negative outcomes has been recognized by the Institute of Medicine (Cancer Care for the Whole Patient, 2008) and research published in the Journal of Clinical Oncology (J Clin Oncol 26:1355-1363). Clinical research findings, utilizing PACE(TM) generated PROs, have also been presented at major oncology conferences by opinion leaders in community oncology and researchers from Duke University.

From a clinical research perspective, PROs gathered by the PACE System allow quantitative measurement of the differences in patients' symptom severity (symptom burden) and quality of life when treated with different cancer regimens. "We are now realizing the scientific value of PROs," states psychologist, Dr. Art Houts, one of the original scientists behind the PACE system. "PROs provide unique and powerful insight into the patient's experience, and we expect they will be useful in predicting and avoiding untoward negative events, thereby improving the patients' ultimate health outcome."

About Supportive Oncology Services, Inc. (SOS)

Supportive Oncology Services, Inc. (SOS), an information and outcomes company, works closely with community oncology practices and oncology academic centers which provide treatment for over a half million cancer patients across the US. SOS also collaborates with bio-technology and pharmaceutical companies, the financial industry, payers, and other cancer-related industry leaders on diverse clinical, financial, and operational initiatives. By continuously offering improvements, measuring results and providing value, SOS helps define and improve the quality of cancer care provided.


'/>"/>
SOURCE Supportive Oncology Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  As people age, it ... multitude of recommended screenings and tests that are linked ... priority. However, for the majority of aging individuals, hearing ... planning. For the 37.5 million American adults who report ... present to make hearing health a 2016 healthy aging ...
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... Ind. , Feb. 5, 2016  Zimmer Biomet ... pricing of the previously announced underwritten secondary offering of ... its stockholders, consisting of affiliates of Blackstone and Goldman ... at an initial price of $96.45 per share. The ... the offering.  Neither Zimmer Biomet nor any of its ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... At its annual meeting held last week, the American ... National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We ... Chambers , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled ... provide the most effective tattoo removal today, Dr. Bentkover is the only doctor in ... Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) as ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is ... one drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect ... package includes a 3D slideshow environment with 1 to 5 focus points per scene, ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Health and wellness ... relevant to individuals in the event they are experiencing an illness. Migraines are a ... Americans that are afflicted with migraines would not wish the pain on their worst ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
Breaking Medicine News(10 mins):